Eurocine Vaccines has completed dosing of its quadrivalent influenza vaccine candidate, Immunose™ FLU, in the second clinical study

– In the perspective of this year’s severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer.

-The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without loosing sight of our vision, to offer the first nasal influenza vaccine for children younger than 2 years, adds Hans Arwidsson, CEO of Eurocine Vaccines.

The strategy behind this present study, and its design, was presented in a previous news release dated February 7th, 2018 and can be read here =>

The progress of the study can also be followed at; https://clinicaltrials.gov

Results are expected second half of 2018.

Do you want to follow Eurocine Vaccines development?

Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.

Start your subscription here »